ATP13A3 and neuroblastoma: While it remains unclear whether ATP13A3 levels can be used to predict responsiveness to DFMO, we noted a trend toward an increase in ATP13A3 protein levels in response to DFMO treatment of neuroblastoma cells (data not shown).